胍基化修饰损害载脂蛋白A-I在慢性肾脏病进展中的抗炎和抗氧化特性
该研究纳入82例CKD 2-5期患者,用质谱检测HDL主要蛋白apoA-I的翻译后修饰,发现胍基化apoA-I随CKD进展而增加,从CKD 3期起显著升高。体外模拟胍基化修饰的apoA-I功能实验显示,胍基化损害其抗炎和抗氧化特性,并激活巨噬细胞炎症激酶。
要点
- CKD 2-5期患者血浆apoA-I胍基化水平随CKD进展而增加,从3期起显著升高。
- 胍基化修饰损害apoA-I的抗炎和抗氧化功能,并激活巨噬细胞炎症激酶。
- 胍基化apoA-I升高可能参与CKD相关心血管并发症的分子机制。
核心结论
- CKD患者apoA-I发生胍基化修饰,该修饰损害apoA-I抗炎和抗氧化特性,可能与CKD相关心血管并发症相关。
研究设计与样本
- 研究纳入82例CKD 2-5期患者,分离血浆并用质谱检测apoA-I翻译后修饰。
- 体外用O-methylisourea bisulfate模拟CKD患者apoA-I的修饰模式,并进行功能实验。
主要发现
- 胍基化apoA-I水平随CKD进展而增加,从CKD 3期起升高显著。
- 胍基化apoA-I损害其抗炎和抗氧化特性。
- 胍基化apoA-I激活巨噬细胞中的炎症激酶。
- 血浆中高胍基化apoA-I肽水平被检出,提示CKD病理生理中的新蛋白修饰方面。
临床怎么用
- 该发现提示CKD患者apoA-I功能改变与胍基化修饰相关,可能为理解CKD相关心血管并发症提供分子机制线索。
- 研究强调在CKD患者中减少翻译后修饰的重要性,但尚未提供临床干预方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) substantially heightens the likelihood of cardiovascular events, in part due to the impaired functionality of high-density lipoprotein (HDL) and its connection with atherosclerosis. Here, 82 patients with CKD stages 2-5 had their plasma isolated and analyzed using mass spectrometry to detect post-translational modifications of apolipoprotein A-I (apoA-I), the main protein component of HDL. Guanidinylation, a non-enzymatic post-translational modification, led to increased levels of apoA-I with CKD progression. The increase in guanidinylated apoA-I became significant from CKD stage 3 onwards. The modification patterns of apoA-I in patients with CKD were mimicked in vitro by exposure to O-methylisourea bisulfate. The thus modified apoA-I was used for functional assays which revealed that guanidinylation compromised the anti-inflammatory and anti-oxidative properties of apoA-I, of potential relevance for clinical findings. Specifically, guanidinylated apoA-I activated inflammatory kinases in macrophages, suggesting a mechanistic link between apoA-I modifications and inflammatory responses. These findings are in favor of alterations in the functional properties of apoA-I in patients with CKD due to guanidinylation. The identification of high guanidinylated apoA-I peptide levels in plasma highlights a novel aspect of protein modification in CKD pathophysiology. The results of our study may provide a better understanding of the molecular mechanisms underlying CKD-related cardiovascular complications and highlight the importance and the need to minimize post-translational modifications in patients with CKD.
引用
- Bonnin-Marquez A, Jankowski J, Maas SL, et al. Guanidinylation compromises the anti-inflammatory and anti-oxidative properties of apolipoprotein A-I in chronic kidney disease progression. Kidney Int. 2025. PMID: 40010491. doi:10.1016/j.kint.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。